Sensome’s latest developed Clotild is focused on treating ischemic strokes. The company stated that even though there are numerous methods available for the treatment of the blocked brain arteries, it is difficult to ensure the right treatment or to control it, without identifying the composition of the clot first.
Emergent BioSolutions, Gaithersburg, Maryland-based Biopharmaceutical Company announced that it will invest $50 million for the next three years to expand the manufacturing capacity for its Camden fill-finish in Baltimore facility. By the time the project has been completed in three years, it is expected to add up 60 jobs.
The UK Based, Wasdell Group a leading service provider for the pharma and medical industries, is planning to invest $671,000 to support its pharma manufacturing through a laboratory project; before the end of this year, the company is also planning to move into sterile manufacturing.
Scott Gottlieb, FDA Commissioner is looking for help from Facebook and Twitter to slow down the unauthorized opioid sales in the US. Gottlieb invited the two social media giants, among others, to participate in the FDA Online Opioid Summit which is set for June 27.
It has been stated by the women and their families taking legal actions mentioned that the cancer was caused by decade-long use of J&J’s Baby Powder and other cosmetic. The petitioners have alleged that the company failed to warn consumers about cancer risks in spite of the knowledge that its talc was contaminated with asbestos at least since the 1970s.
San Francisco-based company iBeat, an mHealth wearable development company has announced new funding from form SCOR Life & Transamerica Ventures and Health Ventures for its mHealth devices, Heart Watch which continuously monitors the heart.. iBeat did not state what the total amount was, only that the investments round was “upward of seven figures”.
This will be the second recall on a heart device this month Medtronic’s Heartware device and accessories was recalled a few days ago. This comes after Abbott issued a patch to negate cybersecurity issues 350,000 remote monitoring systems and pacemakers.
This week Apple announced that researchers and app developers can now have access to a Health Record API (Application Programming Interface) to develop applications, with the permission to use the patient’s data to provide them with easy access to health records.
Along with new drug partner Merck, the British drugmaker displayed results showing that adding Lynparza to Johnson & Johnson prostate cancer fighter Zytiga was a more potent disease-fighter than Zytiga alone. As compared to a time-frame of 8.2 months for solo Zytiga, the combo effectively prevented disease progression for 13.8 months.
Updated clinical data on its T-cell therapies has been presented by Adaptimmune. The GlaxoSmithKline-partnered NY-ESO SPEAR T-cells have been linked by the latest readouts to a 50% partial response rate in heavily pretreated cancer patients and have led to the positioning of Adaptimmune for dialing up of dosing of two wholly owned assets.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.